IL1RAP antibodies engineered to block IL1‐signaling and to enhance ADCC activity have shown strong therapeutic effects in patient‐derived chronic myeloid leukemia (CML) and AML xenograft models [53, 54]. Here, IL1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.